Efficacy and Tolerability of OROS Hydromorphone in Strong Opioid-Naive Patients: An Open Label, Prospective Study / 대한내과학회지
Korean Journal of Medicine
;
: 317-322, 2011.
Article
in Korean
| WPRIM
| ID: wpr-23779
ABSTRACT
BACKGROUND/AIMS:
OROS hydromorphone is a synthetic opioid agent. While clinical studies have tested its effectiveness at controlling cancer-associated pain in patients who have received other strong opioids, no clinical studies have tested its effectiveness at managing cancer pain in strong opioid-naive patients. We performed the present study to evaluate the efficacy and tolerability of OROS hydromorphone in strong opioid-naive cancer patients.METHODS:
We administered OROS hydromorphone to patients who had not received strong opioids during the previous month. The starting dose was 8 mg/day. The dose was increased every 2 days in patients who experienced more than four episodes of breakthrough pain per day (more than four times in patients being treated with short-acting opioids). We evaluated the efficacy, safety and tolerability of ORS hydromorphone. We also evaluated patient satisfaction and investigators' global assessments.RESULTS:
We enrolled 23 patients to the study. The decrease in the numeric rating scale (NRS) was 59%. NRS variation had decreased markedly during the previous 24 h. All patients achieved stable pain control. The side effects were similar to those of other strong opioids. In total, 26% of patients were very satisfied with the treatment and 47% satisfied, and 74% of the investigators deemed OROS hydromorphone to be very effective or effective at controlling cancer pain.CONCLUSIONS:
OROS hydromorphone is an osmotically driven, controlled-release preparation that is very effective and safe when administered once daily to strong opioid-naive cancer patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Research Personnel
/
Prospective Studies
/
Patient Satisfaction
/
Delayed-Action Preparations
/
Hydromorphone
/
Electrolytes
/
Breakthrough Pain
/
Analgesics, Opioid
Type of study:
Observational study
/
Risk factors
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS